Prof. Dr. GÜLEN HATEMİ

Yayın Ağı

Makaleler 177

1. Factors associated with thrombosis in Behçet Syndrome: A systematic review and meta-analysis

Guzelant-Ozkose G., Yurttas B., ESATOĞLU S. N., AR M. C., Hamuryudan V., HATEMİ G.

Seminars in Arthritis and Rheumatism , cilt.73, 2025 (SCI-Expanded, Scopus)

2. Variability in phenotype clusters of Behçet's syndrome: A systematic review

Macit B., ESATOĞLU S. N., Akyuz-Yesilyurt K., HATEMİ G.

Seminars in Arthritis and Rheumatism , cilt.73, 2025 (SCI-Expanded, Scopus)

3. Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry

Sota J., Ragab G., AlMaglouth I., Lopalco G., TUFAN A., DİRESKENELİ R. H., et al.

Joint Bone Spine , cilt.92, sa.2, 2025 (SCI-Expanded, Scopus)

4. Development of Posterior Uveitis in Behçet Syndrome Patients with Vitreous Cells at Baseline

Uçar D., Bircan B. E., Rustamli N., Batu Oto B., Hamuryudan V., Hatemi G., et al.

Ocular Immunology and Inflammation , cilt.33, sa.2, ss.243-249, 2025 (SCI-Expanded, Scopus)

5. New and future perspectives in Behçet's syndrome

Sulu B., Hatemi G.

ARCHIVES OF RHEUMATOLOGY , cilt.39, sa.4, ss.511-521, 2024 (SCI-Expanded, Scopus, TRDizin)

6. Tocilizumab may not be a good option for vascular involvement due to Behçet's syndrome.

Ozdede A., ESATOĞLU S. N., Durmaz E. Ş., Karakoc A., Ogun H., HATEMİ G., et al.

Clinical and experimental rheumatology , cilt.42, sa.10, ss.2057-2064, 2024 (SCI-Expanded, Scopus)

7. Behçet’s syndrome: one year in review 2024

Hatemi G., Seyahi E., Fresko İ., Talarico R., Uçar D., Hamuryudan V.

Clinical and Experimental Rheumatology , cilt.42, sa.10, ss.1999-2007, 2024 (SCI-Expanded, Scopus)

8. Mimickers of nervous system involvement among patients with Behçet's syndrome

Nas E. D., ÇALIŞKAN E., Gulec Z. E., UYGUNOĞLU U., Tutuncu M., Saip S., et al.

JOURNAL OF NEUROLOGY , cilt.271, sa.10, ss.6903-6911, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Behcet's Disease Immune Landscape Exhibits a Universal NFkB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype

Özgüler Y., Manches O., Uçar D., Lin Z., Khodadadi-Jamayran A., Tsirigos A., et al.

ARTHRITIS & RHEUMATOLOGY , ss.5125, 2024 (SCI-Expanded, Scopus)

10. Skin Microbiome Shows Differences Between Pathergy Positive and Negative Patients with Behcet's Syndrome

Sarac B., KALKANCI A., KILIÇ E., ŞAHİN E. A., ÖZGÜLER Y., HATEMİ G.

ARTHRITIS & RHEUMATOLOGY , ss.5124, 2024 (SCI-Expanded, Scopus)

11. De novo manifestations during adalimumab treatment in Behçet's syndrome

ESATOĞLU S. N., SÖNMEZ Ö., UÇAR D., Kaymaz E., ÖZGÜLER Y., UĞURLU S., et al.

RHEUMATOLOGY , 2024 (SCI-Expanded, Scopus)

12. Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions

ERDOĞAN M., Kilickiran Avci B., Ebren C., Ersoy Y., Ongen Z., Ongen G., et al.

Clinical and Experimental Rheumatology , cilt.42, sa.8, ss.1590-1597, 2024 (SCI-Expanded, Scopus)

13. Validation of the Behçet's Syndrome Overall Damage Index (BODI) for retrospective studies and a proposal for modification

Ozogul Y. Y., ÖZGÜLER Y., ESATOĞLU S. N., UÇAR D., UYGUNOĞLU U., KUTLUBAY Z., et al.

RHEUMATOLOGY , 2024 (SCI-Expanded, Scopus)

14. Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.

ERDOĞAN M., ESATOĞLU S. N., Kilickiran Avci B., HATEMİ G.

Internal and emergency medicine , cilt.19, sa.3, ss.731-743, 2024 (SCI-Expanded, Scopus)

15. A Proposal of a New Tool for the Assessment of Damage in Behçet Syndrome Uveitis: Cerrahpasa Ocular Damage Grading System

Ozyazgan Y., UÇAR D., BATU OTO B., ESATOĞLU S. N., ÖZGÜLER Y., HATEMİ G., et al.

Ocular Immunology and Inflammation , cilt.32, sa.10, ss.2332-2338, 2024 (SCI-Expanded, Scopus)

16. Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis

UÇAR D., ESATOĞLU S. N., Cerme E., BATU OTO B., Hamuryudan V., SEYAHİ E., et al.

Rheumatology International , cilt.43, sa.11, ss.2099-2106, 2023 (SCI-Expanded, Scopus)

17. Development of Posterior Uveitis in Behcet's Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

UÇAR D., Bircan B. E., RUSTAMLI N., BATU OTO B., HAMURYUDAN V., ESATOĞLU S. N., et al.

ARTHRITIS & RHEUMATOLOGY , ss.3072-3073, 2023 (SCI-Expanded, Scopus)

18. Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behcet Syndrome

ESATOĞLU S. N., GÜNER S., Guler S., HATEMİ G., KEPİL N., ERZİN Y. Z., et al.

ARTHRITIS & RHEUMATOLOGY , ss.3068-3070, 2023 (SCI-Expanded, Scopus)

19. De Novo Manifestations During Adalimumab Treatment in Behcet Syndrome

ESATOĞLU S. N., SÖNMEZ Ö., UÇAR D., Kaymaz E., ÖZGÜLER Y., UĞURLU S., et al.

ARTHRITIS & RHEUMATOLOGY , ss.3070-3072, 2023 (SCI-Expanded, Scopus)

20. Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis

Erdogan M., ESATOĞLU S. N., KILIÇKIRAN AVCI B., HATEMİ G.

ARTHRITIS & RHEUMATOLOGY , ss.3001-3003, 2023 (SCI-Expanded, Scopus)

21. Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis

Ozogul Y. Y., ESATOĞLU S. N., Ozogul M., KIZILKILIÇ O., ÖZGÜLER Y., Uygunoglu U., et al.

ARTHRITIS & RHEUMATOLOGY , ss.3063-3065, 2023 (SCI-Expanded, Scopus)

22. Behcet's Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity

Nowatzky J., Lin Z., Ozguler Y., Khodadadi-Jamayran A., UÇAR D., Tsirigos A., et al.

ARTHRITIS & RHEUMATOLOGY , ss.1376, 2023 (SCI-Expanded, Scopus)

23. Axial Spondyloarthritis in Patients with Gastrointestinal Involvement of Behcet Syndrome

ÖZTÜRK M., ESATOĞLU S. N., HATEMİ A. İ., ÇELİK A. F., KARGIN O. A., ÖZ A., et al.

ARTHRITIS & RHEUMATOLOGY , ss.3067-3068, 2023 (SCI-Expanded, Scopus)

24. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome

Mease P. J., HATEMİ G., Paris M., Cheng S., Maes P., Zhang W., et al.

American Journal of Clinical Dermatology , cilt.24, sa.5, ss.809-820, 2023 (SCI-Expanded, Scopus)

25. Therapeutic approach to central nervous system involvement of Behçet's disease

Sota J., Capuano A., Emmi G., Iannone F., Cantarini L., HATEMİ G., et al.

Seminars in Arthritis and Rheumatism , cilt.61, 2023 (SCI-Expanded, Scopus)

26. Behcet Syndrome

HATEMİ G., Ucar D., Uygunoglu U., Yazici H., Yazici Y.

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA , cilt.49, sa.3, ss.585-602, 2023 (SCI-Expanded, Scopus)

27. Treatment of systemic sclerosis-associated digital ulcers: recommendations of the Turkish Society for Rheumatology

Karadag D. T., Yalcinkaya Y., AKDOĞAN A., Avanoglu A., Bes C., BİRLİK A. M., et al.

Clinical and Experimental Rheumatology , cilt.41, sa.8, ss.1679-1687, 2023 (SCI-Expanded, Scopus)

28. Sistemik lupus eritematozusda plazma değişim tedavisi: Tek merkez retrospektif kohort çalışması

Özgüler Y., Ak T., Esatoğlu S. N., Elverdi T., Eşkazan A. E., Uğurlu S., et al.

Ulusal Romatoloji Dergisi , cilt.15, sa.2, ss.89-94, 2023 (TRDizin)

29. Conventional and molecular cytogenetic analyses in Behçet’s syndrome patients with gastrointestinal involvement

Esatoğlu S. N., Yılmaz Ş., Hatemi G., Kuru R. D., Çırakoğlu A., Hatemi A. İ., et al.

Ulusal Romatoloji Dergisi , cilt.15, sa.2, ss.95-101, 2023 (Scopus, TRDizin)

30. Musculoskeletal manifestations in children with Behcet's syndrome: data from the AIDA Network Behcet's Syndrome Registry

Gaggiano C., Maselli A., Sfikakis P. P., Laskari K., Ragab G., Hegazy M. T., et al.

INTERNAL AND EMERGENCY MEDICINE , cilt.18, sa.3, ss.743-754, 2023 (SCI-Expanded, Scopus)

31. Difficult-to-treat Beh?et syndrome: A therapeutic approach

Yazici Y., HATEMİ G.

CLINICAL IMMUNOLOGY , cilt.249, 2023 (SCI-Expanded, Scopus)

32. Treat to target in Behcet's disease: Should we follow the paradigm of other systemic rheumatic diseases?

Fragoulis G. E., Bertsias G., Bodaghi B., GÜL A., van Laar J., MUMCU G., et al.

Clinical Immunology , cilt.246, 2023 (SCI-Expanded, Scopus)

33. Heat Shock Proteins in Behçet Syndrome

Aydın A. K. K., HATEMİ G.

Balkan Medical Journal , cilt.40, sa.5, ss.314-323, 2023 (SCI-Expanded, Scopus)

34. A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project

Gaggiano C., Del Bianco A., Sota J., Gentileschi S., Ruscitti P., Giacomelli R., et al.

Frontiers in Medicine , cilt.10, 2023 (SCI-Expanded, Scopus)

35. ANCA ile ilişkili vaskülitte plazma değişim tedavisi: Tek merkez retrospektif kohort çalışması

Özgüler Y., Ak T., Esatoğlu S. N., Elverdi T., Eşkazan A. E., Uğurlu S., et al.

Ulusal Romatoloji Dergisi , cilt.14, sa.3, ss.131-136, 2022 (Scopus, TRDizin)

36. Frequency of AA amyloidosis has decreased in Behcet's syndrome: a retrospective study with long-term follow-up and a systematic review Amyloidosis in Behcet's syndrome

Karatemiz G., ESATOĞLU S. N., Gurcan M., ÖZGÜLER Y., YURDAKUL S., HAMURYUDAN V., et al.

RHEUMATOLOGY , cilt.62, sa.1, ss.9-18, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Behcet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity

Cavers A., Kugler M. C., Ozguler Y., Al-Obeidi A. F., HATEMİ G., Ueberheide B. M., et al.

ANNALS OF THE RHEUMATIC DISEASES , cilt.81, sa.11, ss.1603-1611, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

38. Development and implementation of the AIDA International Registry for patients with Behcet's disease

Vitale A., Della Casa F., Ragab G., Almaghlouth I. A., Lopalco G., Pereira R. M., et al.

INTERNAL AND EMERGENCY MEDICINE , cilt.17, sa.7, ss.1977-1986, 2022 (SCI-Expanded, Scopus)

39. Outcome of Vascular Involvement of Behcet Syndrome Treated with Infliximab: A Retrospective Cohort Study

HATEMİ G., TÜKEK N. B., ESATOĞLU S. N., ÖZGÜLER Y., Taflan S. S., MELİKOĞLU M., et al.

ARTHRITIS & RHEUMATOLOGY , ss.3098-3099, 2022 (SCI-Expanded, Scopus)

40. Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16⁺ Monocytes to Effector Sites in Behcet's Disease

Ozguler Y., Lin Z., Cavers A., HATEMİ G., Manches O., Nowatzky J.

ARTHRITIS & RHEUMATOLOGY , ss.3097, 2022 (SCI-Expanded, Scopus)

41. Development of Posterior Uveitis in Behcet's Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

UÇAR D., Bircan B. E., RUSTAMLI N., BATU OTO B., HAMURYUDAN V., ESATOĞLU S. N., et al.

ARTHRITIS & RHEUMATOLOGY , ss.3090-3091, 2022 (SCI-Expanded, Scopus)

42. Validation of Behcet's Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification

Ozogul Y. Y., Ozguler Y., UÇAR D., Uygunoglu U., Kutlubay Z., Hamuryudan V., et al.

ARTHRITIS & RHEUMATOLOGY , ss.3091-3092, 2022 (SCI-Expanded, Scopus)

43. Emergence of new manifestations during infliximab treatment in Behcet's syndrome

Tukek N. B., Esatoglu S. N., HATEMİ G., Caliskan E. B., Ozyazgan Y., Ucar D., et al.

RHEUMATOLOGY , cilt.61, sa.9, ss.3746-3753, 2022 (SCI-Expanded, Scopus)

44. Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates

Hacioglu A., Borekci Ş., Melikoglu M., Ozguler Y., Esatoglu S. N., Ugurlu S., et al.

Rheumatology International , cilt.42, sa.8, ss.1443-1451, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

45. Impact of apremilast on quality of life in Behcet's syndrome: analysis of the phase 3 RELIEF study

HATEMİ G., Mahr A., Takeno M., Kim D., MELİKOĞLU M., Cheng S., et al.

RMD OPEN , cilt.8, sa.2, 2022 (SCI-Expanded, Scopus)

46. Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine

ÖZTAŞ M., BEKTAŞ M., KARACAN İ., Aliyeva N., DAĞ A., Aghamuradov S., et al.

JOURNAL OF MEDICAL VIROLOGY , cilt.94, sa.7, ss.3431-3437, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

47. Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome

Vitale A., Caggiano V., Della Casa F., Hernandez-Rodriguez J., Frassi M., Monti S., et al.

FRONTIERS IN MEDICINE , cilt.9, 2022 (SCI-Expanded, Scopus)

48. Core Set of Domains for Outcome Measures in Behcet's Syndrome

HATEMİ G., Meara A., ÖZGÜLER Y., DİRESKENELİ R. H., Mahr A., Shea B., et al.

ARTHRITIS CARE & RESEARCH , cilt.74, ss.691-699, 2022 (SCI-Expanded, Scopus)

49. Challenges in optimising patient participation in research: do patients participating in meetings represent the actual patient population with Behcet's syndrome?

Taflan S. S., ESATOĞLU S. N., ÖZGÜLER Y., YURTTAŞ B., MELİKOĞLU M., HATEMİ G.

ANNALS OF THE RHEUMATIC DISEASES , cilt.81, ss.448-450, 2022 (SCI-Expanded, Scopus)

50. A treat-to-target approach is needed for Behçet's syndrome.

Hatemi G.

Current opinion in rheumatology , cilt.34, sa.1, ss.39-45, 2022 (SCI-Expanded, Scopus)

51. The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behcet's syndrome

Ozcifci G., Aydin T., Atli Z., BALKAN İ. İ., TABAK Ö. F., ÖZTAŞ M., et al.

RHEUMATOLOGY INTERNATIONAL , cilt.42, sa.1, ss.101-113, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

52. Global epidemiology of vasculitis

Watts R. A., HATEMİ G., Burns J. C., Mohammad A. J.

NATURE REVIEWS RHEUMATOLOGY , cilt.18, sa.1, ss.22-34, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

53. Takayasu arteritis.

Esatoglu S. N., Hatemi G.

Current opinion in rheumatology , cilt.34, sa.1, ss.18-24, 2022 (SCI-Expanded, Scopus)

54. Behcet syndrome

Yazici Y., HATEMİ G., Bodaghi B., Cheon J. H., Suzuki N., Ambrose N., et al.

NATURE REVIEWS DISEASE PRIMERS , cilt.7, sa.1, 2021 (SCI-Expanded, Scopus)

55. COVID-19 Among Patients With Inflammatory Rheumatic Diseases

Esatoglu S. N., Tascilar K., Babaoglu H., Bes C., YURTTAŞ B., AKAR S., et al.

FRONTIERS IN IMMUNOLOGY , cilt.12, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

56. Aortic involvement in relapsing polychondritis: case-based review.

Erdogan M., Esatoglu S. N., Hatemi G., Hamuryudan V.

Rheumatology international , cilt.41, sa.4, ss.827-837, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

57. One year in review 2021: Behçet's syndrome.

Hatemi G., SEYAHİ E., Fresko I., Talarico R., Ucar D., Hamuryudan V.

Clinical and experimental rheumatology , cilt.39, sa.5, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

58. Recent Insights into the Management of Behcet Syndrome

Ozguler Y., Ozdede A., HATEMİ G.

JOURNAL OF INFLAMMATION RESEARCH , cilt.14, ss.3429-3441, 2021 (SCI-Expanded, Scopus)

59. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.

Hatemi G., Mahr A., Takeno M., Kim D. Y., Saadoun D., DİRESKENELİ R. H., et al.

Clinical and experimental rheumatology , cilt.39, sa.5, 2021 (SCI-Expanded, Scopus)

60. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behcet's syndrome

Ozdede A., HATEMİ G.

EXPERT OPINION ON PHARMACOTHERAPY , cilt.22, ss.1533-1537, 2021 (SCI-Expanded, Scopus)

61. Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study.

Esatoglu S. N., Akkoc-Mustafayev F. N., Ozguler Y., Ozbakır F., NOHUT O. K., Cevirgen D., et al.

Frontiers in immunology , cilt.11, ss.618973, 2020 (SCI-Expanded, Scopus)

62. Clinical Features and Outcomes of Patients with Granulomatosis with Polyangiitis and Review of Literature

ARSLAN E., Oruc M., Yalin S. F., Alagoz S., Demir H., HATEMİ G., et al.

TURKISH JOURNAL OF NEPHROLOGY , cilt.29, sa.4, ss.279-288, 2020 (ESCI, Scopus, TRDizin)

63. One year in review 2020: Behçet's syndrome

Hatemi G., Seyahi E., Fresko İ., Talarico R., HAMURYUDAN V.

Clinical and experimental rheumatology , cilt.38, sa.5, ss.3-10, 2020 (SCI-Expanded, Scopus)

64. Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide.

Gurcan M., Esatoglu S. N., Hamuryudan V., Saygin D., Ugurlu S., Seyahi E., et al.

Rheumatology (Oxford, England) , cilt.59, sa.9, ss.2264-2271, 2020 (SCI-Expanded, Scopus)

65. Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey

Ayan G., Esatoglu S. N., Hatemi G., HAMURYUDAN V.

RHEUMATOLOGY INTERNATIONAL , cilt.40, sa.7, ss.1037-1044, 2020 (SCI-Expanded, Scopus)

66. How to treat myelodysplastic syndrome with clinical features resembling Behcet syndrome: a case-based systematic review

Yilmaz U., Ar M. C., Esatoglu S. N., Bavunoglu I., Erzin Y. Z., Hatemi A. İ., et al.

ANNALS OF HEMATOLOGY , sa.6, ss.1193-1203, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

67. Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome

Ozguler Y., Hatemi G., Cetinkaya F., Tascilar K., Hamuryudan V., Ugurlu S., et al.

Rheumatology (United Kingdom) , cilt.59, sa.4, ss.799-806, 2020 (SCI-Expanded, Scopus)

68. Comment on: Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome: Reply

Ozguler Y., Hatemi G., Cetinkaya F., Tascilar K., Hamuryudan V., Ugurlu S., et al.

Rheumatology (United Kingdom) , cilt.59, sa.4, ss.914-915, 2020 (SCI-Expanded, Scopus)

69. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis

Hellmich B., Agueda A., Monti S., Buttgereit F., de Boysson H., Brouwer E., et al.

ANNALS OF THE RHEUMATIC DISEASES , cilt.79, sa.1, ss.19-30, 2020 (SCI-Expanded, Scopus)

70. Treating the Different Phenotypes of Behcet's Syndrome

Bettiol A., HATEMİ G., Vannozzi L., Barilaro A., Prisco D., Emmi G.

FRONTIERS IN IMMUNOLOGY , cilt.10, 2019 (SCI-Expanded, Scopus)

71. Bone marrow oedema on sacroiliac/spine MRI: is it really a sign of objective inflammation warranting treatment?

Esatoglu S. N., Hatemi G.

Clinical and experimental rheumatology , sa.6, ss.10, 2019 (SCI-Expanded, Scopus)

72. Tapering tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective study.

Hacioglu A., Hatemi G., Esatoglu S. N., Hamuryudan V.

Clinical and experimental rheumatology , sa.6, ss.8, 2019 (SCI-Expanded, Scopus)

73. The improper use of a no-treatment group in the randomised surgical trial for subacromial shoulder pain.

Guzelant G., Hatemi G.

Clinical and experimental rheumatology , ss.9, 2019 (SCI-Expanded, Scopus)

74. One year in review 2019: Behçet's syndrome

Hatemi G., Seyahi E., Fresko İ., Talarico R., Hamuryudan V.

Clinical and experimental rheumatology , cilt.37, sa.6, ss.3-17, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

75. Disease Course of Behcet's Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation

Esatoglu S. N., Bilgin S., Sulu C., Hamuryudan V., Kutlubay Z., MELİKOĞLU M., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.71, 2019 (SCI-Expanded, Scopus)

76. Pentoxifylline Gel for Oral Ulcers in Patients with Behcet's Syndrome

HATEMİ G., Yurttas B., Kutlubay Z., Cote T., Derkunt S. B., Yazici Y., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.71, 2019 (SCI-Expanded, Scopus)

77. Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018

Aydin S. Z., Robson J. C., Sreih A. G., Hill C., Alibaz-Oner F., Mackie S., et al.

JOURNAL OF RHEUMATOLOGY , cilt.46, sa.9, ss.1198-1201, 2019 (SCI-Expanded, Scopus)

78. Acknowledged statistical help and a better use of p values: a proposal.

Dincses E., Guzelant G., Hatemi G., Sut N., Yazici H.

Clinical and experimental rheumatology , cilt.37, sa.5, ss.855-857, 2019 (SCI-Expanded, Scopus)

79. Update on the treatment of Behcet's syndrome

ESATOĞLU S. N., HATEMİ G.

INTERNAL AND EMERGENCY MEDICINE , cilt.14, sa.5, ss.661-675, 2019 (SCI-Expanded, Scopus)

80. Behcet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils

Emmi G., Becatti M., Bettiol A., HATEMİ G., Prisco D., Fiorillo C.

FRONTIERS IN IMMUNOLOGY , cilt.10, 2019 (SCI-Expanded, Scopus)

81. Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome.

Leccese P., Ozguler Y., Christensen R., Esatoglu S. N., Bang D., Bodaghi B., et al.

Seminars in arthritis and rheumatism , cilt.48, sa.4, ss.752-762, 2019 (SCI-Expanded, Scopus)

82. Management of large-vessel vasculitis

Salvarani C., HATEMİ G.

CURRENT OPINION IN RHEUMATOLOGY , cilt.31, sa.1, ss.25-31, 2019 (SCI-Expanded, Scopus)

83. Biosimilar infliximab for Behcet's syndrome: a case series

Dincses E., Esatoglu S. N., Ozguler Y., Uygunoglu U., Hamuryudan V., Seyahi E., et al.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.37, sa.6, ss.111-115, 2019 (SCI-Expanded, Scopus)

84. Patients' experiences with Behcet's syndrome: structured interviews among patients with different types of organ involvement

Ozguler Y., Merkel P. A., Gurcan M., Bocage C., Eriksen W., Kutlubay Z., et al.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.37, sa.6, ss.28-34, 2019 (SCI-Expanded, Scopus)

85. Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.

Ozguler Y., Leccese P., Christensen R., Esatoglu S. N., Bang D., Bodaghi B., et al.

Rheumatology (Oxford, England) , cilt.57, sa.12, ss.2200-2212, 2018 (SCI-Expanded, Scopus)

86. Highlights of the 18th International Conference on Behçet's syndrome

ESATOĞLU S. N., Kutlubay Z., HATEMİ G.

Clinical and experimental rheumatology , cilt.36, sa.6, ss.3-12, 2018 (SCI-Expanded, Scopus)

87. Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement

Esatoglu S. N., Hatemi I., Ozguler Y., Hatemi G., Uzun H., Celik A. F., et al.

Clinical and experimental rheumatology , cilt.36, sa.6, ss.90-96, 2018 (SCI-Expanded, Scopus)

88. Acknowledged Biostatistical Help and the Quality of Statistical Analyses in Randomized Controlled Trials in Rheumatology

Dincses E., Guzelant G., Hatemi G., Yazici H.

ARTHRITIS & RHEUMATOLOGY , cilt.70, 2018 (SCI-Expanded, Scopus)

89. Retrospective Analysis of Initial Presentation Findings of Behcet's Syndrome throughout 4 Decades

Dincses E., Ozguler Y., Ucar D., Ozyazgan Y., Ugurlu S., Hatemi G., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.70, 2018 (SCI-Expanded, Scopus)

90. Efficacy of Apremilast for Oral Ulcers Associated with Active Behcet's Syndrome over 28 Weeks: Results from a Phase III Study

Hatemi G., Mahr A., Ishigatsubo Y., Song Y. W., Melikoglu M., Cheng S., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.70, 2018 (SCI-Expanded, Scopus)

91. Efficacy of Apremilast for Oral Ulcers Associated with Active Behcet's Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics

Hatemi G., Mahr A., Takeno M., Kim D., Melikoglu M., Cheng S., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.70, 2018 (SCI-Expanded, Scopus)

92. Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration.

Ozguler Y., Yazici Y., Hatemi G., Tascilar K., Yazici H.

Pharmacoepidemiology and drug safety , cilt.27, sa.8, ss.894-901, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

93. 2018 update of the EULAR recommendations for the management of Behçet's syndrome.

Hatemi G., Christensen R., Bang D., Bodaghi B., Celik A. F., Fortune F., et al.

Annals of the rheumatic diseases , cilt.77, sa.6, ss.808-818, 2018 (SCI-Expanded, Scopus)

94. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies

Ayan G., Esatoglu S. N., Hatemi G., Ugurlu S., Seyahi E., Melikoglu M., et al.

RHEUMATOLOGY INTERNATIONAL , cilt.38, sa.4, ss.607-622, 2018 (SCI-Expanded, Scopus)

95. türkiye romatoloji derneği aksiyel spondilartrit ulusal tedavi önerileri

HATEMİ G., AKAR S., AKDOĞAN A., ATAGÜNDÜZ M. P., ersözlü e. d., ESATOĞLU S. N., et al.

ulusal romatoloji dergisi , 2018 (Hakemli Dergi)

96. Türkiye romatoloji derneği aksiyel spondiloartrit ulusal tedavi önerileri

HATEMİ G., AKAR S., AKDOĞAN A., ATAGÜNDÜZ M. P., ersözlü e. d., ESATOĞLU S. N., et al.

Ulusal romatoloji dergisi , 2018 (Hakemli Dergi)

97. Gastrointestinal Involvement in Behcet Disease

Hatemi I., Hatemi G., Celik A. F.

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA , cilt.44, sa.1, ss.45-65, 2018 (SCI-Expanded, Scopus)

98. Behcet syndrome: a contemporary view

Yazici H., Seyahi E., Hatemi G., Yazici Y.

NATURE REVIEWS RHEUMATOLOGY , cilt.14, sa.2, ss.107-119, 2018 (SCI-Expanded, Scopus)

99. Biomarkers in vasculitis.

Hatemi G., Esatoglu S. N., Yazici Y.

Current opinion in rheumatology , cilt.30, sa.1, ss.30-35, 2018 (SCI-Expanded, Scopus)

100. One year in review 2018: Behçet’s syndrome

Hatemi G., Seyahi E., Fresko İ., TALARICO R., Hamuryudan V.

Clinical and Experimental Rheumatology , cilt.36, sa.6, 2018 (SCI-Expanded, Scopus)

101. Considerations in designing and interpreting prevalence studies for Behcet syndrome

Hatemi G., Esatoglu S. N., Yurdakul S.

POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ , cilt.128, sa.3, ss.148-149, 2018 (SCI-Expanded, Scopus)

102. Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.

Guzelant G., Ucar D., Esatoglu S. N., Hatemi G., Ozyazgan Y., Yurdakul S., et al.

Clinical and experimental rheumatology , sa.6, ss.86-89, 2017 (SCI-Expanded, Scopus)

103. Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016.

Hatemi G., Meara A., Ozguler Y., Direskeneli H., Mahr A., Easley E., et al.

The Journal of rheumatology , cilt.44, sa.11, ss.1750-1753, 2017 (SCI-Expanded, Scopus)

104. Method

Hatemi G.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

105. Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis

Ozguler Y., Esatoglu S. N., Karatemiz G., Unal A. U., Guzelant G., Dincses E., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.69, 2017 (SCI-Expanded, Scopus)

106. Behçet's syndrome: providing integrated care.

Esatoglu S. N., Kutlubay Z., Ucar D., Hatemi I., Uygunoglu U., Siva A., et al.

Journal of multidisciplinary healthcare , cilt.10, ss.309-319, 2017 (Scopus)

107. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Esatoglu S. N., Hatemi G., Ugurlu S., Gokturk A., Tascilar K., Ozdogan H.

Medicine , cilt.96, sa.34, 2017 (SCI-Expanded, Scopus)

108. Behçet's disease: an MHC-I-opathy?

Hatemi G., KARATEMIZ G., YAZICI H.

Clinical and experimental rheumatology , ss.5, 2017 (SCI-Expanded, Scopus)

109. Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals

Yurdakul S., Ayan G., Ozguler Y., Hatemi G., Ugurlu S., Seyahi E., et al.

European Journal of Internal Medicine , cilt.37, 2017 (SCI-Expanded, Scopus)

110. One year in review 2017: Behçet's syndrome

Hatemi G., Seyahi E., Fresko İ., Talarico R., Hamuryudan V.

Clinical and Experimental Rheumatology , cilt.35, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

111. Systemic vasculitis and the gut

Hatemi A. İ., Hatemi G., Çelik A. F.

CURRENT OPINION IN RHEUMATOLOGY , cilt.29, sa.1, ss.33-38, 2017 (SCI-Expanded, Scopus)

112. Apremilast for the treatment of Behcet's syndrome

Hatemi G., Yazici Y.

EXPERT OPINION ON ORPHAN DRUGS , cilt.5, sa.8, ss.677-681, 2017 (SCI-Expanded, Scopus)

113. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy

Ozguler Y., Hatemi G., Ugurlu S., Seyahi E., Melikoglu M., Borekci Ş., et al.

RHEUMATOLOGY INTERNATIONAL , cilt.36, sa.12, ss.1719-1725, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

114. EARLIER USE OF INFLIXIMAB FOR THE UVEITIS OF BEHCET'S SYNDROME APPEARS TO BE ASSOCIATED WITH BETTER OUTCOME

Guzelant G., Ucar D., Hatemi G., Ozyazgan Y., Esatoglu N. S., Yurdakul S., et al.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.34, sa.6, 2016 (SCI-Expanded, Scopus)

115. One year in review 2016: Belicet's syndrome

Hatemi G., Seyahi E., Fresko İ., TALARICO R., Hamuryudan V.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.34, sa.6, 2016 (SCI-Expanded, Scopus)

116. Identifying Core Domains for BehcEt's Syndrome Trials: An International Physician and Patient Delphi Exercise

Meara A., Ozguler Y., Mahr A., Direskeneli H., Gül A., Yazici Y., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.68, 2016 (SCI-Expanded, Scopus)

117. Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behcet's Syndrome Patients with Gastrointestinal Involvement: A Controlled Study

Esatoglu S. N., Hatemi I., Ozguler Y., Hatemi G., Uzun H., Celik A. F., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.68, 2016 (SCI-Expanded, Scopus)

118. Associated Inflammatory Diseases in Takayasu's Arteritis: The Many Faces of a Disease

Esatoglu S. N., Celik A. M., UÇAR D., Celik A. F., UĞURLU S., HATEMİ G., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.68, 2016 (SCI-Expanded, Scopus)

119. Diagnostic Criteria as Separate From Classification Criteria: A Perpetual Motion Machine? Comment on the Article by Aggarwal et al.

Yazici H., Hatemi G., YAZICI Y.

Arthritis care & research , cilt.68, ss.1049, 2016 (SCI-Expanded, Scopus)

120. Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al.

YAZICI H., OZGULER Y., Hatemi G., YAZICI Y.

Arthritis & rheumatology (Hoboken, N.J.) , cilt.68, ss.1315-6, 2016 (SCI-Expanded, Scopus)

121. Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet’s Syndrome

HATEMİ A. İ., ESATOĞLU S. N., HATEMİ G., ERZİN Y. Z., YAZICI H., ÇELİK A. F.

MEDICINE , cilt.95, 2016 (SCI-Expanded, Scopus)

122. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.

Kisacik B., Pamuk O. N., Onat A. M., Erer S. B., Hatemi G., Ozguler Y., et al.

The Journal of rheumatology , cilt.43, sa.3, ss.524-9, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

123. Management of Behçet's syndrome.

Ozguler Y., Hatemi G.

Current opinion in rheumatology , cilt.28, sa.1, ss.45-50, 2016 (SCI-Expanded, Scopus)

124. Highlights of the 17th International Conference on Behçet's syndrome

ESATOĞLU S. N., HATEMİ G., Leccese P., Olivieri I.

Clinical and Experimental Rheumatology , cilt.34, ss.3-9, 2016 (SCI-Expanded, Scopus)

125. Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12

AYDIN S. Z., DIRESKENELI H., SREIH A., ALIBAZ-ONER F., GÜL A., KAMALI S., et al.

JOURNAL OF RHEUMATOLOGY , cilt.42, sa.12, ss.2465-2469, 2015 (SCI-Expanded, Scopus)

126. Ocular Involvement of Behcet's Syndrome: a Comprehensive Review

Ozyazgan Y., Ucar D., Hatemi G., Yazici Y.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY , cilt.49, sa.3, ss.298-306, 2015 (SCI-Expanded, Scopus)

127. Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.

Hatemi G., Ozguler Y., Direskeneli H., Mahr A., GÜL A., LEVI V., et al.

The Journal of rheumatology , cilt.42, sa.12, ss.2436-41, 2015 (SCI-Expanded, Scopus)

128. A reappraisal of the association between Behcet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review

Esatoglu S. N., Hatemi G., Çelik A. F., Hatemi I., Soysal T., Çelik A. B.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.33, sa.6, 2015 (SCI-Expanded, Scopus)

129. Suicidal ideation among patients with Behcet's syndrome

Saygin C., Uzunaslan D., Hatemi G., Hamuryudan V.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.33, sa.6, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

130. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature

Hatemi A. İ., Hatemi G., Pamuk Ö. N., Erzin Y. Z., Çelik A. F.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.94, sa.6, ss.129-137, 2015 (SCI-Expanded, Scopus)

131. Assessing the Possible Association of Anti-TNF Use with New Neoplasms: An Important Methodological Consideration

Ozguler Y., Yazici Y., Hatemi G., Yazici H.

ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus)

132. Work Disability over Time in Behcet's Syndrome

Hatemi G., Tascilar K., Ozguler Y., Ugurlu S., Hamuryudan V.

ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus)

133. Fragmented Qrs Patterns Do Not Correlate with the Degree of Lung and Skin Involvement in Patients with Systemic Sclerosis

Uzunaslan D., Saygin C., Kostek M., Özdemir M., Torun T., Altay S., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus)

134. Restarting biologic agents in rheumatology patients who developed tuberculosis under TNF alpha-inhibitor treatment

Ozguler Y., Hatemi G., Ugurlu S., Seyahi E., Melikoglu M., Borekci S., et al.

EUROPEAN RESPIRATORY JOURNAL , cilt.46, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

135. Differences and similarities in rheumatology specialty training programmes across European countries

SIVERA F., RAMIRO S., CIKES N., DOUGADOS M., GOSSEC L., KVIEN T. K., et al.

ANNALS OF THE RHEUMATIC DISEASES , cilt.74, sa.6, ss.1183-1187, 2015 (SCI-Expanded, Scopus)

136. Apremilast for Behçet's syndrome - A phase 2, placebo-controlled study

Hatemi G., Melikoglu M., Tunc R., Korkmaz C., Ozturk B. T., Mat C., et al.

New England Journal of Medicine , cilt.372, sa.16, ss.1510-1518, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

137. Double pylorus in a patient with Behçet's syndrome.

Hatemi A. İ., Hatemi G., Erzin Y. Z., Çelik A. F.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.94, sa.6, ss.138-140, 2015 (SCI-Expanded, Scopus)

138. Currently Used Biologic Agents in the Management of Behcet's Syndrome

Saygin C., Uzunaslan D., Hatemi G.

CURRENT MEDICINAL CHEMISTRY , cilt.22, sa.16, ss.1976-1985, 2015 (SCI-Expanded, Scopus)

139. Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet's syndrome: A comparative clinical survey

Buyuktas D., HATEMİ G., Yuksel-Findikoglu S., UĞURLU S., Yazici H., Yurdakul S.

Clinical and Experimental Rheumatology , cilt.33, ss.107-112, 2015 (SCI-Expanded, Scopus)

140. Tuberculosis Reactivation Risk in Patients Treated with Tumor Necrosis Factor Alpha Inhibitors: A Turkish Experience with Higher Mortality and Different Background Diseases.

Kisacik B., Pamuk O., Onat A. M., Erer B., Hatemi G., Ozguler Y., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

141. Predictors of Quality of Life in Behcet's Syndrome.

Bozcan S., Ozguler Y., Tascilar K., Saygin C., Uzunaslan D., Hatemi G.

ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus)

142. Anti-TNF Treatment for Refractory Vascular Involvement of Behcet's Syndrome.

Hamuryudan V., Seyahi E., Melikoglu M., Ugurlu S., Hatemi G., Yurdakul S., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus)

143. Fatigue in Systemic Sclerosis

Uzunaslan D., Saygin C., Torun T., Özdemir M., Hatemi G.

ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus)

144. Effect of Apremilast on Quality of Life and Physical Function in Patients with Behcet's Syndrome.

Hatemi G., Melikoglu M., Tunc R., Korkmaz C., ÖZTÜRK B. T., Mat C., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus)

145. No appreciable decrease in fertility in Behcet's syndrome

Uzunaslan D., Saygin C., Hatemi G., Tascilar K., Yazici H.

RHEUMATOLOGY , cilt.53, sa.5, ss.828-833, 2014 (SCI-Expanded, Scopus)

146. Outcome Measures Used in Clinical Trials for Behcet Syndrome: A Systematic Review

Hatemi G., Merkel P. A., Hamuryudan V., Boers M., Direskeneli H., Aydin S. Z., et al.

JOURNAL OF RHEUMATOLOGY , cilt.41, sa.3, ss.599-612, 2014 (SCI-Expanded, Scopus)

147. Current Status of Outcome Measure Development in Vasculitis

Merkel P. A., Aydin S. Z., Boers M., Cornell C., Direskeneli H., Gebhart D., et al.

JOURNAL OF RHEUMATOLOGY , cilt.41, sa.3, ss.593-598, 2014 (SCI-Expanded, Scopus)

148. Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behets syndrome patients

YÜKSEL Ş., Eren E., Hatemi G., Sahillioglu A. C., Gultekin Y., Demiroz D., et al.

INTERNATIONAL IMMUNOLOGY , cilt.26, sa.2, ss.71-81, 2014 (SCI-Expanded, Scopus)

149. Predictors of Quality Of Life in Behcet's Syndrome

Bozcan S., Ozguler Y., Saygin C., Uzunarslan D., Tascilar E. K., Ugurlu S., et al.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.32, sa.4, 2014 (SCI-Expanded, Scopus)

150. Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behcet's Syndrome

Nava F., Ghilotti F., Maggi L., Hatemi G., Del Bianco A., Merlo C., et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS , sa.12, 2014 (SCI-Expanded, Scopus)

151. Tuberculosis Screening Before and During Treatment with Tumor Necrosis Factor Antagonists: Something Old, Something New

Hatemi G., Yazici H.

JOURNAL OF RHEUMATOLOGY , cilt.40, sa.12, ss.1938-1940, 2013 (SCI-Expanded, Scopus)

152. Behcet's syndrome: a critical digest of the 2012-1213 literature

Hatemi G., Seyahi E., Fresko I., Hamuryudan V.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.31, sa.3, 2013 (SCI-Expanded, Scopus)

153. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists

Hatemi G., Melikoglu M., Ozbakir F., Tascilar K., Yazici H.

Arthritis Research and Therapy , cilt.14, sa.3, 2012 (SCI-Expanded, Scopus)

154. The papulopustular lesion/arthritis cluster of Behcet's syndrome also clusters in families

Karaca M., Hatemi G., SÜT N., Yazici H.

RHEUMATOLOGY , cilt.51, sa.6, ss.1053-1060, 2012 (SCI-Expanded, Scopus)

155. Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?

Yonal O., Hatemi G., Kaymakoglu S.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.23, ss.21-24, 2012 (SCI-Expanded, Scopus, TRDizin)

156. Do anti-TNF agents and combination treatment increase postoperative complication risk?

Yonal O., Hatemi G., Hamzaoglu H. O.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.23, ss.25-29, 2012 (SCI-Expanded, Scopus, TRDizin)

157. Behcet's syndrome and micro-organisms

Hatemi G., Yazici H.

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY , cilt.25, sa.3, ss.389-406, 2011 (SCI-Expanded, Scopus)

158. Analyses of functional IL10 and TNF-alpha genotypes in Behcet's syndrome

Ates O., Dalyan L., Hatemi G., Hamuryudan V., Topal-Sarikaya A.

MOLECULAR BIOLOGY REPORTS , cilt.37, sa.7, ss.3637-3641, 2010 (SCI-Expanded, Scopus)